Oura files to go public

Oura filed for an IPO, reporting revenue rising from $697M (nine months ended June 30 last year) to $1.2B for the corresponding nine months this year, alongside 3.6M rings sold and ~5M paid members with ~85% 12-month retention. The company targets ~$2B revenue this year and highlights an AI/ML health platform supported by ~42B hours of physiological data. Offsetting the growth story, a proposed class action alleges misleading sleep-tracking accuracy, though Oura says it will defend against the claims.

Analysis

The market read-through is less about one private issuer and more about whether public investors are willing to pay software multiples for a consumer device with recurring revenue. If that answer is yes, the relative winners are the platforms that can bundle health data, services, and distribution at scale; the losers are hardware-only wearables that rely on one-time device replacement and have weaker monetization after the sale. That argues for a multiple expansion regime for names with ecosystem lock-in, but only if the underlying retention is durable rather than novelty-driven.

The real near-term risk is not growth, it is trust. A consumer health business whose differentiation depends on biometric accuracy is one adverse ruling, disclosure issue, or product recall away from seeing its AI narrative discounted as marketing rather than defensible IP. The integration push into employers and payers also increases regulatory surface area: the same data asset that supports a higher valuation can become a privacy and liability overhang if the company cannot prove clinical utility.

Over the next 1-3 months, the pricing of the IPO will be the cleanest signal on whether the market is buying the subscription + data story or simply the growth headline. Over 6-18 months, the more important test is whether cohort retention and paid conversion stay high once the novelty cycle rolls over; if not, the dataset’s strategic value decays faster than bulls expect. The contrarian view is that the moat may be distribution and brand, not measurement depth, which makes the current enthusiasm vulnerable to normalization after listing.

Key Decisions for Investors

• Long AAPL vs. short GRMN for 3-6 months: express the view that premium health wearables with services attach deserve a higher multiple than hardware-heavy peers; stop if Garmin’s recurring revenue mix or guidance reaccelerates meaningfully.
• Set a watch alert on OURA IPO pricing and first-week trading only; if the deal clears at a valuation implying >10x forward sales, expect a sentiment lift for consumer health/data names, but do not chase without seeing retention and CAC disclosed post-listing.
• Avoid initiating new longs in consumer-wearable proxies until litigation risk is clearer; a clean read on the sleep-accuracy suit is the key falsifier for any premium multiple re-rating in the category.
• If the IPO trades well but the first earnings call shows slowing paid-member growth or falling retention, fade the move in AAPL/GRMN on any sympathy rally: that would signal the market overpaid for a one-cycle engagement story.